Write short notes on the following in about 150 words each :
(c) Gene therapy and its significance.
10 marks · answer in 150 words · directive: Write short notes
The core of a good answer
Gene therapy treats disease by delivering a functional gene or editing a faulty one in a patient's cells, usually somatic cells, either ex vivo (cells modified outside and returned, as for ADA-SCID in 1990 or CAR-T cells) or in vivo (a vector such as AAV given directly, as in Luxturna in 2017 and Zolgensma in 2019); it offers one-time cures for monogenic disorders such as sickle cell disease and thalassaemia, but cost, safety and ethics remain concerns.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
Define, classify (somatic or germline; ex vivo or in vivo), name the vectors, give landmark cases and weigh significance and limits in about 150 words.
Answer outline
Introduction
Gene therapy aims at a therapeutic effect through manipulation of gene expression or alteration of living cells.
Types
- Somatic gene therapy: changes limited to the patient; germline therapy: heritable, prohibited in many countries.
- Ex vivo: patient's cells modified in the lab and reinfused (CAR-T, Casgevy); in vivo: vector delivered into the body (Luxturna, Zolgensma).
Vectors
- Viral: retroviruses and lentiviruses (integrate), adenoviruses (transient), adeno-associated virus (mostly episomal).
- Non-viral: naked DNA, electroporation, lipoplexes, nanoparticles; CRISPR-Cas9 for editing.
Landmarks
- 1990: Ashanti DeSilva treated for ADA-SCID at the NIH.
- 1999: death of Jesse Gelsinger in an adenovirus trial impeded gene therapy research in the US.
- 2012: Glybera, first approved gene therapy in the West; 2017: Kymriah and Luxturna (US); 2019: Zolgensma for spinal muscular atrophy; December 2023: Casgevy for sickle cell disease approved by the US FDA.
Significance and limits
- Potential cure for single-gene disorders, cancers (CAR-T), inherited blindness.
- Limits: immune reactions, insertional mutagenesis, very high cost, ethical issues of heritable germline changes.
Conclusion
Gene therapy has moved from experiment to approved medicine; its future depends on safer delivery and affordable access.
Examples and data to cite
- Zolgensma (onasemnogene abeparvovec) was approved by the US FDA in May 2019 for spinal muscular atrophy in children under two.
- Luxturna (voretigene neparvovec), approved in December 2017, was the first in vivo gene therapy approved in the US.
Facts to remember
- Germline gene therapy is prohibited in countries including Australia, Canada, Germany, Israel, the Netherlands and Switzerland.
- AAV vectors need a helper virus to replicate and persist mostly as episomes.
- Kymriah (tisagenlecleucel), approved in August 2017, treats acute lymphoblastic leukaemia.